Serial use of aprotinin and incidence of allergic reactions.
Allergic reactions to aprotinin, a polypeptide, have been reported on several occasions. A survey of 136 courses of aprotinin, given to patients with gastric cancer as a protease inhibitor, has shown an incidence of less than 1% of acute anaphylaxis and a similar incidence of minor allergic responses. Two cases of acute allergic responses are described. Fifteen patients received repeated courses of aprotinin at 6-weekly intervals and no allergic phenomena were detected. Provided patients are challenged intra-dermally or with eye drops before each course, it is considered that aprotinin is safe to use in repeated fashion.
D007611:Aprotinin / Q000008:administration & dosage / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004342:Drug Hypersensitivity; D006801:Humans; D008297:Male; D008875:Middle Aged; D012306:Risk; D013274:Stomach Neoplasms / Q000188:drug therapy
D007611:Aprotinin